| Lizenz: Allianz- bzw. Nationallizenz PDF - Veröffentlichte Version (242kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-344728
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.34472
Zusammenfassung
Objective The objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. Methods The GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags